Table 1.
Parameter table
| Parameter | Value | Notes | |
|---|---|---|---|
| PWID population size: | All sampled from a normal distribution | ||
| Amsterdam | 2621 (1946–3374) in 2009 1874 (1341–2455) in 2014 |
||
| Belgium | 9080 (6356 – 11804) | ||
| Czech Republic | 41816 – 46563 | Range – no point estimate available | |
| Denmark | 16500 (13000 – 19000) | ||
| Finland | 15611 (13770 – 22655) | ||
| France | 80000 (65000 – 95000) | ||
| Hamburg | 8492 (7582 – 9436) | ||
| Norway | 15500 (10500 – 20150) | ||
| Scotland | 16000 (11500 – 19400) | ||
| Slovenia | 6000 (4200 – 7800) | ||
| Sweden | 8021 – 26550 | Maximum and minimum PWID population size estimates. | |
| PWID mortality rate: | All sampled from a Poisson distribution | ||
| Amsterdam | 2.4% per year | ||
| Belgium | 2.5% per year | ||
| Czech Republic | 0.8% per year | ||
| Denmark | 2.0% per year | ||
| Finland | 2.0% per year | ||
| France | 1.3% per year | ||
| Hamburg | 0.7% per year | ||
| Norway | 1.9% per year | ||
| Scotland | 1.0% per year | ||
| Slovenia | 0.7% per year | ||
| Sweden | 2.0% per year | ||
| HCV antibody prevalence among PWID and year prevalence fit to | All sampled from a normal distribution. In all cases HCV antibody prevalence is adjusted to chronic prevalence by assuming a 26% (22–29%) spontaneous clearance rate [54] |
||
| Amsterdam | 59.4% (54.8 – 64.0%) | 2007 | |
| Belgium | 43.3% (34.3 – 52.4%) | 2012 | |
| Czech Republic | 35.0% (31.6 – 38.5%) | 2005 | |
| Finland | 76.0% (72.4–79.4%) | 2014 | |
| France | 66.4% (60.3–71.9%) | 2011 | |
| Hamburg | 67.7% (62.3–72.8%) | 2014 | |
| Scotland | 58.0% (55.8 – 60.2%) | 2013/14 | |
| Slovenia | 27.3% (19.1 – 35.5%) | mid-2010 | |
| Sweden | 81.7% (79.6 – 83.6%) | 2014 | |
| HCV chronic prevalence among PWID | |||
| Denmark | 35.0 – 45.0% | 2014 | |
| Norway | 45% (42.6 – 47.5%) | 2007 | |
| Number PWID treated per year: | 1. Only those on OST are initially eligible for treatment. 2. All PWID can be treated. |
||
| Total treated in each site per year | Number treated per 1000 PWID per year | ||
| Amsterdam | 2005–2016: 15 | 2005–2016: 6.1 – 11.2 | 1. |
| Belgium | 2004–2016: 30 | 2004–2016: 5.7 – 10.6 | 1. |
| Czech Republic | 2002–2011: 370 2011–2016: 540 |
2002–2011: 7.9 – 8.8 2011–2016: 11.6 – 12.9 |
2. |
| Denmark | 2002–2014: 53 2014–2015: 50 2014–2016: 100 |
2002–2014: 2.8 – 4.1 2014–2015:2.6–3.8 2014–2016: 5.3–7.7 |
1. |
| Finland | 2006–2016: 5 | 2006–2016: 0.06 | 1. |
| France | 2001–2016: 1705 (923 – 3148) |
2001–2016:10.5 – 43.3 | 1. Note: these are the calculated number treated based on the treatment rate for people who have injected at least one in the last year. |
| Hamburg | 2005–2011: 60 2011–2016: 72 |
2005–2011: 6.2 – 7.9 2011–2016: 7.6 – 9.5 |
1. |
| Norway | 2009–2016: 100 | 2009–2016: 5.0 – 9.5 | 70% treatment are amongst those on OST and 30% treatment amongst those not on OST. |
| Scotland | 2005–2008: 60 2008–2009: 90 2009–2016: 150 |
2005–2008: 3.1 – 5.2 2008–2009: 4.6–7.8 2009–2016: 7.7–13.0 |
1. |
| Slovenia | 1997–1999: 2 1999–2008: 5 2008–2016: 62 |
1997–1999: 0.3 – 0.5 1999–2008: 0.6 – 1.2 2008–2016: 7.9 – 14.8 |
2. |
| Sweden | 1997–2016: 90 | 1997–2016: 3.4 – 11.2 | 2. |
Key parameters used in the modelling for each of the sites. PWID population size and prevalence estimates shows mean (95% CI) unless otherwise stated. Mortality rates are given per year. The range for the number of PWID treated per 1000 PWID is estimated using the number of treatments in each site and the PWID population size. References are given in Tables S1a-S1k in Supplementary Material.